drugset / Trial / NCT01940952

Zydena on Cognitive Function of Alzheimer's Disease Patients

NCT01940952

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Zydena (Udenafil) has positive effect on cognitive function in patients with Alzheimer's disease. This study is a randomized, double blind, placebo-controlled multicenter study.

Timeline

Start
2013-09
Primary completion
2015-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Udenafil Small molecule 50 mg
Comparator Udenafil Small molecule 100 mg
Comparator Donepezil Small molecule 5 mg
Comparator Donepezil Small molecule 10 mg

Indications